ATC Against The Clock okładka

ATC Against The Clock

ATC Against The Clock

Autor: ATC Pod
Słuchaj bezpłatnie, bez subskrypcji

Das größte Angebot der Saison | 0,99 € pro Monat für die ersten 3 Monate + 15 € Audible-Guthaben

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
O tym tytule

Against The Clock is a roundtable with four physicians who practice longevity and performance medicine: Bhavesh Patel, MD in Chicago, Shahab Mokhtare, MD in Las Vegas, Keith A. Fleischman, DO in New York, and Stephanie Singer, DO in Park City.

Each episode takes up the questions patients bring to their offices: GLP-1 drugs, hormones for women and men, peptides, stem cells, supplements, sleep, and the studies behind the headlines. The hosts prescribe these treatments and follow patients on them for years, and they do not always agree with each other. The disagreements stay in the recording.

New episodes weekly, with show notes and articles at theatcpod.com. For general information only. Not medical advice, and listening does not create a doctor-patient relationship.

2026 ATC Pod
  • Ai in Medicine, Whole-Body MRI, and Robot Doctors
    Nov 19 2026

    What happens when AI starts reading your chart, your scans, and your wearable data? Four physicians talk through how they are already using AI in patient care, where it helps, where it worries them, and what it cannot replace.

    AI in the chart. AI is already helping with notes and documentation, and it can surface things a busy clinician misses. One case in this episode: AI helped catch a cause of restless legs that had been overlooked.

    Robots and the human side. If a robot can take a history and run an exam, what is left for the doctor? The group works through where automation fits, where it does not, and what happens to the human side of medicine as these tools spread.

    AI and drug discovery. AI is speeding up the search for new drugs. The question is how much of the promise is real today and how much is still ahead of the evidence.

    Wearables and the data patients bring in. Oura, Whoop, Eight Sleep, Apple Watch, continuous glucose monitors. Patients now arrive with months of their own data, including one case where a Garmin reading at altitude pointed to a change in a patient's blood count. The hard part is knowing which numbers deserve action.

    Whole-body MRI. The second half closes with screening scans: what a whole-body MRI finds, what it misses, and what happens when it turns up something incidental. A finding is not the same as a diagnosis, and a scan is not right for everyone. The episode ends on personalized screening, matching the test to the person instead of scanning everyone the same way.

    Timestamps
    00:05 AI in medicine: where this is going
    00:56 AI in patient care
    06:05 The charting case AI helped catch
    11:22 Robots and the future of AI
    15:28 What AI cannot replace
    19:18 AI and drug discovery
    26:23 Quality of life vs longevity
    33:58 Wearables: Oura, Whoop, Eight Sleep, Apple Watch
    37:30 Continuous glucose monitors
    39:55 Altitude, hemoglobin, and wearable data
    42:00 Whole-body MRI
    44:26 What MRI misses
    47:31 Incidental findings and prostate screening
    51:03 Personalized screening

    Show notes, articles, and the newsletter are at theatcpod.com. Follow @theatcpod on YouTube, TikTok, and X, and @the.atc.pod on Instagram.

    Disclaimer
    This podcast is for general informational and educational purposes only. It is not medical advice, diagnosis, or treatment, and it does not create a physician-patient relationship or any other professional healthcare relationship. The views expressed are the hosts' and guests' own and are not a substitute for advice from your own healthcare professional. Always consult your personal healthcare provider about your health, and never disregard or delay professional care because of information in this podcast. Reliance on any information in this podcast is solely at your own risk.

    Rozwiń Zwiń
    53 min
  • Peptides, Stem Cells, and the FDA Conspiracy?
    Nov 15 2026

    One of us walked into a stem cell workshop a skeptic and walked out rethinking it. Four longevity physicians work through stem cells and peptides: how these products actually work, why the rules differ by country, and whether the missing evidence is a conspiracy or just economics.


    Stem cells are signals, not spare parts. Injected cells do not become new cartilage or tendon. They release exosomes, tiny vesicles carrying signals that tell your own tissue to repair itself. The cell is a factory for signals, which is why the quality of each cell matters more than the count in the syringe.


    Quality over quantity. Clinics overseas market cell counts in the millions. Growing cells in culture to hit those numbers dilutes the signaling each cell produces. A smaller number of potent cells can out-signal a larger number of expanded ones.


    Why patients fly out. In the US, your own fat or bone marrow, minimally processed and reinjected, is the practice of medicine. Placental or umbilical cells grown in culture become a biologic drug that needs FDA approval, which none has for these uses. That is why the expanded-cell treatments happen in Mexico, Panama, and Colombia, and why a US product is at least traceable and clean.


    Exosomes versus stem cells. Exosomes are the signal, ready on delivery. Stem cells keep producing the signal for weeks. Exosomes were offered in US offices until the FDA removed them, and that status has not changed.


    Conspiracy corner: peptides. In October 2026 the FDA said it would not pursue 503A compounding pharmacies or their prescribers over a short list of peptides, including BPC-157 and TB-500. That is enforcement discretion. It is not an approval, and it is not a finding that any of them is safe or effective.


    Why there are no human trials. These compounds have been described since the 1970s, and there is still almost no human trial evidence. The arguments: a fragment of a protein your body already makes is hard to patent, a trial program costs hundreds of millions, and the gray market already sells the compounds everywhere. The simpler explanation also got its hearing: if they worked clearly, the money would have shown up by now.


    Timestamps

    00:00 Intro from Franklin, Tennessee

    03:26 The stem cell workshop: what changed a skeptic's mind

    06:27 Sourcing: placenta, bone marrow, fat, and what the FDA allows

    09:11 Exosomes explained

    12:40 Why patients go to Mexico and Panama

    16:32 Exosomes vs. stem cells: which, and when

    23:38 Quality over quantity, and clean up the pool first

    26:07 Is it a longevity treatment at all?

    31:46 Conspiracy corner: peptides and the FDA

    33:44 Why pharma hasn't patented them

    38:53 Where are the human trials?

    47:18 Why the FDA may have loosened up

    52:06 Take-home: stem cells in practice


    Show notes, articles, and the newsletter are at theatcpod.com. Follow @theatcpod on YouTube, TikTok, and X, and @the.atc.pod on Instagram.


    Disclaimer

    This podcast is for general informational and educational purposes only. It is not medical advice, diagnosis, or treatment, and it does not create a physician-patient relationship or any other professional healthcare relationship. The views expressed are the hosts' and guests' own and are not a substitute for advice from your own healthcare professional. Always consult your personal healthcare provider about your health, and never disregard or delay professional care because of information in this podcast. Reliance on any information in this podcast is solely at your own risk.


    Rozwiń Zwiń
    56 min
adbl_web_anon_alc_button_suppression_t1
Brak recenzji